BIO Pacific Rim Summit to Address Innovation and Future of Advanced Biofuels and Biorefinery Development, Renewable Chemicals, Biomass Utilization, and Synthetic Biology

Aug 7 2012
The Biotechnology Industry Organization (BIO) today announced more than 100 speakers covering the latest in industrial biotechnology at the 2012 Pacific Rim Summit on Industrial Biotechnology and Bioenergy

BIO Unveils Preliminary Program for the 2012 BIO Convention in China

Aug 7 2012
Event to take place in Shanghai, China, October 24-25, 2012 .

BIO Urges EPA and Congress to Stay the Course on the Renewable Fuel Standard

Aug 3 2012
Waiving the federal Renewable Fuel Standard even for one year will produce instability in the program for several years, causing uncertainty for companies investing in advanced biofuels and for farmers growing next-generation energy crops. 

Renewable Chemical Production Tax Credit Will Help U.S. Biotech Companies Create Jobs, BIO Says

Aug 3 2012
Producing renewable chemicals and biobased products using homegrown biotechnology can generate additional employment opportunities across the United States, the Biotechnology Industry Organization (BIO) and its member companies said today. 

BIO Thanks Sens. Baucus, Hatch, Senate Finance Committee for Extending Tax Policy That Drives Innovation

Aug 2 2012
The Biotechnology Industry Organization (BIO) today thanked Sens. Max Baucus (D-Mont.) and Orrin Hatch (R-Utah) and members of the Senate Finance Committee. 

BIO Issues Call for Sessions for 2013 BIO International Convention

Aug 1 2012
The global event for biotech will take place in Chicago, IL, April 22-25, 2013.

BIO Opposes A Northern California County's New Drug Disposal Law

Jul 27 2012
The measure forces certain companies to pay for disposal.

Biotech Leader Provides Testimony at Congressional Hearing on Sarbanes-Oxley

Jul 26 2012
The House Subcommittee on Capital Markets held a hearing entitled “The 10th Anniversary of the Sarbanes-Oxley Act.” Jeff Hatfield, President and CEO of Vitae Pharmaceuticals, presented testimony about the effects of regulatory burdens in Sarbanes-Oxley.

IFPMA, BIO and WADA Advance Anti-Doping Collaboration with the Launch of 2 Fields 1 Goal Campaign

Jul 23 2012
Groups issue booklet to help biotechnology and pharmaceutical companies identify pipeline medicines with doping potential.

BIO Praises Rep. Michael Fitzpatrick on Introduction of Fostering Innovation Act

Jul 20 2012
New bill will update SEC filing status classifications to ease costly regulatory burdens on small public companies